PPI Modulators of E6 as Potential Targeted Therapeutics for Cervical Cancer: Progress and Challenges in Targeting E6
Advanced cervical cancer is primarily managed using cytotoxic therapies, despite evidence of limited efficacy and known toxicity. There is a current lack of alternative therapeutics to treat the disease more effectively. As such, there have been more research endeavors to develop targeted therapies...
Main Authors: | Lennox Chitsike, Penelope J. Duerksen-Hughes |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-05-01
|
Series: | Molecules |
Subjects: | |
Online Access: | https://www.mdpi.com/1420-3049/26/10/3004 |
Similar Items
-
Drug discovery by targeting the protein–protein interactions involved in autophagy
by: Honggang Xiang, et al.
Published: (2023-11-01) -
Screening of small molecular compounds with carcinogenic inhibition function of HPV-16 E6
by: Jiaoyu He, et al.
Published: (2023-08-01) -
A small-molecule inhibitor of MDMX suppresses cervical cancer cells via the inhibition of E6-E6AP-p53 axis
by: Jingwen Zhang, et al.
Published: (2022-03-01) -
The Efficacy of Therapeutic DNA Vaccines Expressing the Human Papillomavirus E6 and E7 Oncoproteins for Treatment of Cervical Cancer: Systematic Review
by: Ayazhan Akhatova, et al.
Published: (2021-12-01) -
RIPOR2 Expression Decreased by HPV-16 E6 and E7 Oncoproteins: An Opportunity in the Search for Prognostic Biomarkers in Cervical Cancer
by: Leslie Olmedo-Nieva, et al.
Published: (2022-12-01)